Sana Historical Financial Ratios

SANA Stock

USD 2.61 0.26 11.06%

Sana Biotechnology is promptly reporting on over 91 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Book Value Per Share of 1.55, Invested Capital of 0.0, Average Payables of 2.8 M or Stock Based Compensation To Revenue of 0.0 will help investors to properly organize and evaluate Sana Biotechnology financial condition quickly.

Quick Ratio Current Ratio

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sana Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Sana Stock refer to our How to Trade Sana Stock guide.

About Sana Financial Ratios Analysis

Sana BiotechnologyFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Sana Biotechnology investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Sana financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Sana Biotechnology history.

Sana Biotechnology Financial Ratios Chart

At present, Sana Biotechnology's PTB Ratio is projected to increase significantly based on the last few years of reporting. The current year's Book Value Per Share is expected to grow to 1.55, whereas Free Cash Flow Yield is projected to grow to (0.33).

Dividend Yield Average Payables Net Income Per Share Days Of Inventory On Hand Payables Turnover Return On Equity

Add Fundamental

Dividend Yield

Dividend Yield is Sana Biotechnology dividend as a percentage of Sana Biotechnology stock price. Sana Biotechnology dividend yield is a measure of Sana Biotechnology stock productivity, which can be interpreted as interest rate earned on an Sana Biotechnology investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.

Average Payables

The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.

Payables Turnover

A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.

Return On Equity

Return on Equity is the amount of Sana Biotechnology net income returned as a percentage of Sana Biotechnology equity. Return on equity measures Sana Biotechnology profitability by revealing how much profit Sana Biotechnology generates with the money shareholders have invested. A measure of the profitability of a business in relation to the equity, calculated by dividing net income by shareholder's equity.

Most ratios from Sana Biotechnology's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Sana Biotechnology current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sana Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Sana Stock refer to our How to Trade Sana Stock guide.At present, Sana Biotechnology's PTB Ratio is projected to increase significantly based on the last few years of reporting. The current year's Book Value Per Share is expected to grow to 1.55, whereas Free Cash Flow Yield is projected to grow to (0.33).

	2021	2022	2023	2024 (projected)
Net Debt To EBITDA	0.4	0.27	0.12	0.11
Intangibles To Total Assets	0.18	0.24	0.35	0.34

Net Debt To E B I T D A Intangibles To Total Assets

Sana Biotechnology fundamentals Correlations

	Ptb Ratio	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Average Payables	Capex To Depreciation	Pb Ratio	Free Cash Flow Per Share	Roic	Net Income Per Share	Payables Turnover	Cash Per Share	Pocfratio	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow	Pe Ratio	Return On Tangible Assets	Ev To Free Cash Flow	Earnings Yield	Intangibles To Total Assets	Net Debt To E B I T D A	Current Ratio
Ptb Ratio		0.44	-0.72	-0.92	-0.47	-0.88	1.0	-0.93	-0.65	-0.95	0.94	0.82	1.0	-0.67	1.0	-0.74	-0.73	-0.81	1.0	1.0	-0.69	1.0	-0.76	-0.83	-0.97	-0.96
Book Value Per Share	0.44		-0.62	-0.71	-0.27	-0.58	0.44	-0.7	-0.74	-0.58	0.64	0.38	0.46	0.11	0.45	-0.86	0.05	-0.73	0.46	0.43	-0.09	0.45	-0.63	-0.63	-0.52	-0.59
Free Cash Flow Yield	-0.72	-0.62		0.87	0.65	0.86	-0.72	0.85	0.9	0.71	-0.81	-0.44	-0.74	0.08	-0.74	0.89	0.14	0.92	-0.74	-0.73	0.64	-0.74	0.99	0.64	0.78	0.85
Operating Cash Flow Per Share	-0.92	-0.71	0.87		0.53	0.96	-0.92	1.0	0.85	0.96	-0.96	-0.78	-0.93	0.34	-0.92	0.93	0.49	0.95	-0.93	-0.92	0.58	-0.92	0.89	0.9	0.91	0.95
Average Payables	-0.47	-0.27	0.65	0.53		0.59	-0.47	0.51	0.77	0.46	-0.33	-0.13	-0.48	0.03	-0.48	0.41	0.36	0.71	-0.48	-0.47	0.86	-0.48	0.7	0.25	0.54	0.59
Capex To Depreciation	-0.88	-0.58	0.86	0.96	0.59		-0.88	0.96	0.85	0.94	-0.89	-0.8	-0.89	0.25	-0.89	0.86	0.52	0.94	-0.89	-0.88	0.62	-0.89	0.89	0.9	0.84	0.88
Pb Ratio	1.0	0.44	-0.72	-0.92	-0.47	-0.88		-0.93	-0.65	-0.95	0.94	0.82	1.0	-0.67	1.0	-0.74	-0.73	-0.81	1.0	1.0	-0.69	1.0	-0.76	-0.83	-0.97	-0.96
Free Cash Flow Per Share	-0.93	-0.7	0.85	1.0	0.51	0.96	-0.93		0.83	0.97	-0.96	-0.8	-0.94	0.39	-0.94	0.92	0.52	0.94	-0.94	-0.93	0.58	-0.94	0.88	0.91	0.93	0.96
Roic	-0.65	-0.74	0.9	0.85	0.77	0.85	-0.65	0.83		0.73	-0.72	-0.41	-0.68	-0.04	-0.67	0.87	0.19	0.97	-0.68	-0.66	0.66	-0.67	0.94	0.63	0.72	0.8
Net Income Per Share	-0.95	-0.58	0.71	0.96	0.46	0.94	-0.95	0.97	0.73		-0.93	-0.9	-0.95	0.48	-0.95	0.81	0.69	0.86	-0.95	-0.95	0.56	-0.95	0.75	0.94	0.9	0.91
Payables Turnover	0.94	0.64	-0.81	-0.96	-0.33	-0.89	0.94	-0.96	-0.72	-0.93		0.79	0.94	-0.49	0.94	-0.9	-0.47	-0.86	0.94	0.94	-0.51	0.94	-0.82	-0.88	-0.93	-0.94
Cash Per Share	0.82	0.38	-0.44	-0.78	-0.13	-0.8	0.82	-0.8	-0.41	-0.9	0.79		0.81	-0.48	0.81	-0.6	-0.71	-0.59	0.81	0.81	-0.26	0.81	-0.47	-0.94	-0.68	-0.67
Pocfratio	1.0	0.46	-0.74	-0.93	-0.48	-0.89	1.0	-0.94	-0.68	-0.95	0.94	0.81		-0.64	1.0	-0.76	-0.71	-0.83	1.0	1.0	-0.69	1.0	-0.78	-0.83	-0.97	-0.96
Capex To Operating Cash Flow	-0.67	0.11	0.08	0.34	0.03	0.25	-0.67	0.39	-0.04	0.48	-0.49	-0.48	-0.64		-0.66	0.1	0.77	0.16	-0.64	-0.67	0.43	-0.66	0.1	0.3	0.64	0.54
Pfcf Ratio	1.0	0.45	-0.74	-0.92	-0.48	-0.89	1.0	-0.94	-0.67	-0.95	0.94	0.81	1.0	-0.66		-0.75	-0.72	-0.82	1.0	1.0	-0.69	1.0	-0.77	-0.83	-0.98	-0.96
Days Payables Outstanding	-0.74	-0.86	0.89	0.93	0.41	0.86	-0.74	0.92	0.87	0.81	-0.9	-0.6	-0.76	0.1	-0.75		0.15	0.92	-0.76	-0.74	0.39	-0.75	0.89	0.82	0.78	0.84
Income Quality	-0.73	0.05	0.14	0.49	0.36	0.52	-0.73	0.52	0.19	0.69	-0.47	-0.71	-0.71	0.77	-0.72	0.15		0.36	-0.71	-0.73	0.57	-0.72	0.22	0.53	0.63	0.56
Roe	-0.81	-0.73	0.92	0.95	0.71	0.94	-0.81	0.94	0.97	0.86	-0.86	-0.59	-0.83	0.16	-0.82	0.92	0.36		-0.83	-0.81	0.68	-0.82	0.96	0.77	0.85	0.91
Ev To Operating Cash Flow	1.0	0.46	-0.74	-0.93	-0.48	-0.89	1.0	-0.94	-0.68	-0.95	0.94	0.81	1.0	-0.64	1.0	-0.76	-0.71	-0.83		1.0	-0.69	1.0	-0.78	-0.83	-0.97	-0.96
Pe Ratio	1.0	0.43	-0.73	-0.92	-0.47	-0.88	1.0	-0.93	-0.66	-0.95	0.94	0.81	1.0	-0.67	1.0	-0.74	-0.73	-0.81	1.0		-0.69	1.0	-0.76	-0.82	-0.97	-0.96
Return On Tangible Assets	-0.69	-0.09	0.64	0.58	0.86	0.62	-0.69	0.58	0.66	0.56	-0.51	-0.26	-0.69	0.43	-0.69	0.39	0.57	0.68	-0.69	-0.69		-0.69	0.7	0.28	0.74	0.73
Ev To Free Cash Flow	1.0	0.45	-0.74	-0.92	-0.48	-0.89	1.0	-0.94	-0.67	-0.95	0.94	0.81	1.0	-0.66	1.0	-0.75	-0.72	-0.82	1.0	1.0	-0.69		-0.77	-0.83	-0.97	-0.96
Earnings Yield	-0.76	-0.63	0.99	0.89	0.7	0.89	-0.76	0.88	0.94	0.75	-0.82	-0.47	-0.78	0.1	-0.77	0.89	0.22	0.96	-0.78	-0.76	0.7	-0.77		0.67	0.81	0.87
Intangibles To Total Assets	-0.83	-0.63	0.64	0.9	0.25	0.9	-0.83	0.91	0.63	0.94	-0.88	-0.94	-0.83	0.3	-0.83	0.82	0.53	0.77	-0.83	-0.82	0.28	-0.83	0.67		0.74	0.76
Net Debt To E B I T D A	-0.97	-0.52	0.78	0.91	0.54	0.84	-0.97	0.93	0.72	0.9	-0.93	-0.68	-0.97	0.64	-0.98	0.78	0.63	0.85	-0.97	-0.97	0.74	-0.97	0.81	0.74		0.99
Current Ratio	-0.96	-0.59	0.85	0.95	0.59	0.88	-0.96	0.96	0.8	0.91	-0.94	-0.67	-0.96	0.54	-0.96	0.84	0.56	0.91	-0.96	-0.96	0.73	-0.96	0.87	0.76	0.99

Click cells to compare fundamentals

Sana Biotechnology Account Relationship Matchups

Sana Biotechnology fundamentals Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Ptb Ratio	(46.13)	(15.63)	3.54	1.49	2.76	2.9
Book Value Per Share	(0.76)	(2.25)	4.38	2.65	1.48	1.55
Free Cash Flow Yield	(0.017)	(0.0246)	(0.11)	(0.42)	(0.34)	(0.33)
Operating Cash Flow Per Share	(0.46)	(0.74)	(1.51)	(1.54)	(1.3)	(1.37)
Pb Ratio	(46.13)	(15.63)	3.54	1.49	2.76	2.9
Free Cash Flow Per Share	(0.6)	(0.86)	(1.69)	(1.65)	(1.41)	(1.48)
Roic	0.94	0.8	(0.41)	(0.44)	(1.14)	(1.08)
Net Income Per Share	(0.7)	(1.49)	(2.07)	(1.41)	(1.46)	(1.53)
Cash Per Share	0.74	3.55	3.31	2.25	1.05	1.48
Pocfratio	(76.9)	(47.7)	(10.26)	(2.56)	(3.13)	(3.29)
Capex To Operating Cash Flow	(0.31)	(0.17)	(0.12)	(0.072)	(0.079)	(0.0829)
Pfcf Ratio	(58.88)	(40.66)	(9.17)	(2.39)	(2.9)	(3.05)
Roe	0.92	0.66	(0.47)	(0.53)	(0.99)	(0.94)
Ev To Operating Cash Flow	(76.53)	(45.23)	(9.7)	(2.33)	(3.01)	(3.16)
Pe Ratio	(50.28)	(23.62)	(7.49)	(2.79)	(2.8)	(2.94)
Return On Tangible Assets	(0.61)	(0.53)	(0.37)	(0.43)	(0.78)	(0.81)
Ev To Free Cash Flow	(58.59)	(38.56)	(8.67)	(2.17)	(2.79)	(2.93)
Net Debt To E B I T D A	0.23	1.18	0.4	0.27	0.12	0.11
Current Ratio	7.28	12.22	5.62	3.99	3.31	3.15
Tangible Book Value Per Share	(1.83)	(3.31)	3.18	1.59	0.45	0.47
Graham Number	3.46	8.67	14.27	9.19	6.96	5.72
Shareholders Equity Per Share	(0.76)	(2.25)	4.38	2.65	1.48	1.55
Capex Per Share	0.14	0.13	0.18	0.11	0.1	0.088
Graham Net Net	(2.24)	(2.59)	0.9	0.53	(0.37)	(0.39)
Enterprise Value Over E B I T D A	(47.11)	(21.74)	(6.82)	(2.63)	(3.03)	(3.18)
Price Earnings Ratio	(50.28)	(23.62)	(7.49)	(2.79)	(2.8)	(2.94)
Price Book Value Ratio	(46.13)	(15.63)	3.54	1.49	2.76	2.9
Price To Operating Cash Flows Ratio	(76.9)	(47.7)	(10.26)	(2.56)	(3.13)	(3.29)
Price To Free Cash Flows Ratio	(58.88)	(40.66)	(9.17)	(2.39)	(2.9)	(3.05)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether Sana Biotechnology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sana Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sana Biotechnology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sana Biotechnology Stock:

How To Invest In Sana

Details

Is Sana Stock a good investment?

Details

What is Sana Biotechnology's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Sana Stock refer to our How to Trade Sana Stock guide.

You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sana Biotechnology. If investors know Sana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sana Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.40)

Return On Assets

(0.31)

Return On Equity

(0.93)

The market value of Sana Biotechnology is measured differently than its book value, which is the value of Sana that is recorded on the company's balance sheet. Investors also form their own opinion of Sana Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Sana Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sana Biotechnology's market value can be influenced by many factors that don't directly affect Sana Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Sana Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sana Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sana Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Price Book Value Ratio	Price Earnings To Growth Ratio
Days Of Payables Outstanding	Dividend Payout Ratio
Price To Operating Cash Flows Ratio	Price To Free Cash Flows Ratio
Pretax Profit Margin	Ebt Per Ebit
Operating Profit Margin	Effective Tax Rate
Company Equity Multiplier	Long Term Debt To Capitalization
Total Debt To Capitalization	Return On Capital Employed
Debt Equity Ratio	Ebit Per Revenue
Quick Ratio	Dividend Paid And Capex Coverage Ratio
Net Income Per E B T	Cash Ratio
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

Sana Historical Financial Ratios

About Sana Financial Ratios Analysis

Sana Biotechnology Financial Ratios Chart

Dividend Yield

Average Payables

Payables Turnover

Return On Equity

Sana Biotechnology fundamentals Correlations

Sana Biotechnology Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Sana Biotechnology fundamentals Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Pb Ratio	+ 1.0	Ptb Ratio
Pocfratio	+ 1.0	Ptb Ratio
Pfcf Ratio	+ 1.0	Ptb Ratio
Ev To Operating Cash Flow	+ 1.0	Ptb Ratio
Pe Ratio	+ 1.0	Ptb Ratio
Ev To Free Cash Flow	+ 1.0	Ptb Ratio

Net Debt To E B I T D A	- 0.98	Pfcf Ratio
Net Debt To E B I T D A	- 0.97	Ev To Free Cash Flow
Net Debt To E B I T D A	- 0.97	Pe Ratio
Net Debt To E B I T D A	- 0.97	Ev To Operating Cash Flow
Net Debt To E B I T D A	- 0.97	Pocfratio
Net Debt To E B I T D A	- 0.97	Pb Ratio